Patient P-01778
Therapy response 51 at the day-84 endpoint (observed).
Responding: response probability 58%, therapy response 58 today; biology is not blocking the drug.
Drift detected on day 83 (HRV −9 ms, resting HR +9 bpm, sleep −0.8 h, gi toxicity +35, inflammatory load +27); the side effect would have been reported on day 91 — 8 days of warning.
8 of 9 scheduled doses in the last 60 days are biologically confirmed (89%). Dose signature: resting HR +4 bpm, HRV −8 ms.
81% of 284 similar trajectories improved after GI-04; if this one does, discontinuation risk is expected to fall from 55% to ~34%. Keeping fat low is worth 4.8 GI points a day on its own. Losing this patient costs €57k; the intervention costs €180.
- 🍽Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- 🍽Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- ✓Track each bowel movement today: time, stool form, urgency, overnight waking
- ✓Keep the current walking rhythm
- 💊Take the scheduled dose as agreed with your care team
- 💊Electrolyte solution, one sachet after any loose stool
Partial adherence; to-dos are being skipped on symptomatic days.
GI burden above 62 for 3 days within the onset window
P-01778 is on day 116 of NBL-101 (LT, baseline S17): response improving, tolerance unstable, GI improving. Over 14 days response moved +6 and GI -10; discontinuation risk is 55%. The state is between basins, heading towards restoration, after diverging from the model on day 83.
Biology sets the gain: FUT2 non-secretor, Low butyrate capacity, Low microbial diversity; butyrate capacity 28/100, diversity 1.8. Pushing it down: Escherichia coli 32.033% (LPS load) (-36), Low butyrate capacity (-28.3), 6 keystone species absent (-21.2). From the daily log: fat +4.8 GI next day, alcohol +4.8 GI next day, histamine +4.7 GI next day, spicy +3.7 GI next day.
Past actions: CR-01 on day 82 → declined.
Next: GI-04 — 81% of 284 similar trajectories improved, 56% probability here. This would be contradicted by a further GI rise within the onset window or falling adherence.
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and events- Day 0 NBL-101 started — Baseline state S17
- Day 82 CR-01 recommended — Clinician Review CR-01
- Day 83 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 83 Patient declined — Not now
What changed?
Trajectory began diverging from predicted response on Day 83.
- Toxicity+27
- GI instability-10
- Inflammatory activity+9
- Treatment adherence+7
What helped?
- Clinician Review CR-01Day 82Declined by patient
- 284 similar trajectories
- 81% showed improvement
- median effect visible after 8 days
Daily trackers
Asset settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Heading towards restoration · 37 from the failing basin, 57 from restoration.
- Daily walks resumedperturbation · steering +3.3
- Escherichia coli 32.033% (LPS load)hidden · steering -36
- Low butyrate capacityhidden · steering -28.3
- 6 keystone species absenthidden · steering -21.2
- Dietary fat loadperturbation · steering -18.3
- Dietary fat loaddetractor · GI +4.8 next day
- Alcoholdetractor · GI +4.8 next day
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Dietary fat load+4.8detractor · 95%
- Alcohol+4.8detractor · 95%
- Histamine load+4.7detractor · 95%
- Spicy / capsaicin+3.7detractor · 90%
- Simple carbohydrates+2.5detractor · 58%
- Insoluble fibre-0.8no signal · 18%
DeepGene damage signature
The metagenomic + host-DNA read-out that initializes this patient's biology and, on retest, measures whether the steering worked.
- 5 opportunists above range: Escherichia coli, Klebsiella pneumoniae, Enterococcus faecium
- 6 keystone species absent
- Shannon 1.92 (expected ≥ 3)
- 11 resistance genes
- Host DNA fragmentation atypical
- Tissue recycling index 64
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 28/100
- Daily logFibre intake low in recent food logs
- Mucosal barrier integrity ↓50
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 54 and rising
- Inflammatory signalling ↑40
- BloodInflammatory load index 62
- WearableHRV 37 ms, trending down
- Autonomic recovery ↓25
- WearableResting HR 73 bpm
- Drug metabolism and exposure ↑20
- BloodToxicity index 63
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Normal metabolizerExpected exposure
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
- HRV
- 41 ms
- Sleep
- 5.8 h
- Steps
- 7,551
- Resting HR
- 71 bpm
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01877 | 42% | S01 | CR-01 | improved | 61 |
| P-01897 | 29% | S01 | SC-12 | improved | 49 |
| P-01746 | 27% | S01 | NP-02 | improved | 40 |
| P-01706 | 25% | S01 | NP-02 | improved | 42 |
| P-01858 | 25% | S01 | ME-01 | improved | 41 |
| P-01725 | 24% | S01 | CR-01 | improved | 62 |
| P-01684 | 22% | S01 | — | — | 64 |
| P-01800 | 22% | S01 | — | — | 36 |
| P-01526 | 21% | S01 | — | — | 65 |
| P-01724 | 21% | S01 | SC-12 | no change | 60 |
| P-01748 | 21% | S01 | — | — | 67 |
| P-01407 | 28% | S02 | GI-04 | improved | 43 |